[Special Stock] HLB Hits Lower Limit Following News of FDA Rejection for Liver Cancer Drug

HLB, along with HLB Life Science, HLB Global, HLB Therapeutics, and HLB Pharmaceutical, all fell to their price limit.

At 9:12 a.m. on the 17th, HLB was trading at 67,100 won, down 29.96% from the previous day. The market capitalization decreased from 12.5 trillion won to 8.8 trillion won.

On the same day, Jin Yang-gon, chairman of the HLB Group, announced via YouTube that the company received a CRL (Complete Response Letter) from the U.S. Food and Drug Administration (FDA) regarding its application for new drug approval for the combination therapy of its 'Riboceranib' and China's Hansoh Pharmaceutical's 'Camrelizumab' as a first-line treatment for liver cancer.